Commentary: Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice
Timothy J. Sargeant- Lysosomal Diseases Research Unit, South Australian Health and Medical Research Institute, Adelaide, SA, Australia
A commentary on
Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice
by Tanaka, Y., Chambers, J. K., Matsuwaki, T., Yamanouchi, K., and Nishihara, M. (2014). Acta Neuropathol. Commun. 2, 78. doi: 10.1186/s40478-014-0078-x
The recent paper by Tanaka and colleagues details the neuropathological consequences of progranulin knock out in a mouse model. Loss of progranulin function by GRN mutation causes neuronal ceroid lipofuscinosis, also known as Batten's disease—a progressive neurodegenerative condition belonging to a class of disorders called lysosomal storage diseases (LSD, reviewed in Kollmann et al., 2013). The unexpected link between GRN and Batten's disease was discovered by genetic analysis of two siblings presenting with neurological symptoms and histopathological signs consistent with LSD (Smith et al., 2012). This unanticipated genetic relationship shows progranulin is pivotal for lysosomal function in the brain, but the mechanism behind why this protein is essential remains unclear.
Of note, Tanaka et al. (2014) show that LSD caused by progranulin deficiency in mice causes severe neurodegeneration in the somatosensory thalamus (ventroposterior medial/ventroposterior lateral thalamic nuclei—VPM/VPL). Here the authors correctly point out that this is a feature shared by other types of murine Batten's disease models (Partanen et al., 2008; Kuronen et al., 2012). However, this has also been observed in other kinds of lysosomal storage disorders and is not specific to the type of storage product found in the lysosome. The lipid-storing LSD Niemann Pick disease type C1 (cholesterol, ganglioside storage), Sandhoff disease (GM2 ganglioside storage), and Gaucher disease (glucosylceramide storage) all show the same pattern of neuronal cell death in the VPM/VPL (Yamada et al., 2001; Farfel-Becker et al., 2011; Sargeant et al., 2011). Why these thalamic nuclei show selective vulnerability to diverse causes of lysosomal disorder remains unclear. It is reasonable to conclude, however, that the cause of cell death probably stems from generic lysosomal dysfunction, not from a build-up of a hypothetical disease-specific metabolite.
Having shown loss of progranulin precipitates pathological features similar to other diverse LSD, the authors of this study discuss the relevance of progranulin haplo-insufficiency to later onset neurodegenerative disease. Heterozygous mutations in the progranulin gene, GRN, cause familial frontotemporal lobar dementia (FTD). This was discovered when Baker et al. (2006) identified mutations in GRN as risk factors for FTD at 17q21, in addition to MAPT, the gene that encodes tau. It is likely that GRN is haplo-insufficient, revealed by heterozygous null GRN mutations in FTD. Remarkably, genetic variation in GRN has also been linked to other late onset neurodegenerative diseases such as Alzheimer's disease (Perry et al., 2013).
There is, however, a more fundamental process that links GRN mutation with late onset disease. It is now clear that progranulin is a bone fide lysosomal protein that is vital for efficient lysosomal function. This is evidenced by its obvious lysosomal subcellular localization (Gowrishankar et al., 2015) as well as its role in LSD. In light of these findings, it is important to extend the discussion presented by Tanaka and colleagues to include parallels between GRN and GBA.
Like GRN, GBA encodes a lysosomal protein (glucocerebrosidase, GCase). Homozygous or compound heterozygous loss of function mutations in this gene cause a lysosomal disorder called Gaucher disease. Like Batten's disease caused by Grn knockout in mice, Gba knockout produces similar neuropathology; both mouse models display conspicuous loss of neurons in the VPM/VPL that is accompanied by marked gliosis (Farfel-Becker et al., 2011; Tanaka et al., 2014). The similarities do not end there. Heterozygous mutations in both of these lysosomal genes are risk factors for late onset neurodegenerative disease. Heterozygous mutation of GBA is over-represented in Parkinson's disease patients (Gan-Or et al., 2008). This was initially uncovered by astute clinical observation (Rogaeva and Hardy, 2008) and the association between genetic variation in GBA and Parkinson's disease has since been corroborated by numerous genetic studies.
The obvious parallels between GBA and GRN haplo-insufficiency raise immediate questions about the nature of pathogenesis in later onset neurodegenerative diseases such as FTD, Alzheimer's disease and Parkinson's disease. Is risk for late onset neurodegenerative disease from mutation in GBA or GRN related to gene-product specific mechanisms? Or is it general inefficiency in lysosomal flux that causes or contributes to late onset neurodegenerative disease? Surely, the fact that mutations in two very different LSD causing genes that also contribute to late onset neurodegenerative disease suggests variation in lysosomal flux is important. This idea has been further corroborated by a study that showed FTD associated with mutation in the lysosomal network gene, CHMP2B, was accompanied by neuronal lysosomal storage material (Clayton et al., 2015).
With this in mind, are mutations in other lysosomal proteins risk factors for late onset neurodegenerative disorders? With over 50 genes that cause lysosomal storage disease (Cox and Cachón-González, 2012) and at least 900 genes involved in maintaining efficient lysosomal network flux (Di Fruscio et al., 2015), there are many potential candidates for genetic contribution to sporadic forms of late onset neurodegenerative disease. Future studies should address key questions presented in this commentary by focussing on the measurement and enhancement of lysosomal flux in late onset neurodegenerative disease.
In conclusion, the study by Tanaka and colleagues directly links homozygous loss of progranulin to other models of LSD. Lysosomal storage of un-degraded material, along with regionally specific neuronal cell death consistent with other diverse lysosomal disease models is strong evidence that progranulin deficiency causes lysosomal storage disease. Further to this, the role of heterozygous GRN mutation in late onset neurodegenerative disorders appears similar to the relationship between GBA, another lysosomal gene, and Parkinson's disease. This suggests generalized reduction in lysosomal network flux may be a key driver of pathogenesis in late onset neurodegenerative disease.
Author Contributions
The author confirms being the sole contributor of this work and approved it for publication.
Conflict of Interest Statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., et al. (2006). Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916–919. doi: 10.1038/nature05016
Clayton, E. L., Mizielinska, S., Edgar, J. R., Nielsen, T. T., Marshall, S., Norona, F. E., et al. (2015). Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. Acta Neuropathol. 130, 511–523. doi: 10.1007/s00401-015-1475-3
Cox, T. M., and Cachón-González, M. B. (2012). The cellular pathology of lysosomal diseases. J. Pathol. 226, 241–254. doi: 10.1002/path.3021
Di Fruscio, G., Schulz, A., De Cegli, R., Savarese, M., Mutarelli, M., Parenti, G., et al. (2015). Lysoplex: an efficient toolkit to detect DNA sequence variations in the autophagy-lysosomal pathway. Autophagy 11, 928–938. doi: 10.1080/15548627.2015.1043077
Farfel-Becker, T., Vitner, E. B., Pressey, S. N., Eilam, R., Cooper, J. D., and Futerman, A. H. (2011). Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum. Mol. Genet. 20, 1375–1386. doi: 10.1093/hmg/ddr019
Gan-Or, Z., Giladi, N., Rozovski, U., Shifrin, C., Rosner, S., Gurevich, T., et al. (2008). Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70, 2277–2283. doi: 10.1212/01.wnl.0000304039.11891.29
Gowrishankar, S., Yuan, P., Wu, Y., Schrag, M., Paradise, S., Grutzendler, J., et al. (2015). Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. Proc. Natl. Acad. Sci. U.S.A. 112, E3699–E3708. doi: 10.1073/pnas.1510329112
Kollmann, K., Uusi-Rauva, K., Scifo, E., Tyynelä, J., Jalanko, A., and Braulke, T. (2013). Cell biology and function of neuronal ceroid lipofuscinosis-related proteins. Biochim. Biophys. Acta 1832, 1866–1881. doi: 10.1016/j.bbadis.2013.01.019
Kuronen, M., Lehesjoki, A. E., Jalanko, A., Cooper, J. D., and Kopra, O. (2012). Selective spatiotemporal patterns of glial activation and neuron loss in the sensory thalamocortical pathways of neuronal ceroid lipofuscinosis 8 mice. Neurobiol. Dis. 47, 444–457. doi: 10.1016/j.nbd.2012.04.018
Partanen, S., Haapanen, A., Kielar, C., Pontikis, C., Alexander, N., Inkinen, T., et al. (2008). Synaptic changes in the thalamocortical system of cathepsin D-deficient mice: a model of human congenital neuronal ceroid-lipofuscinosis. J. Neuropathol. Exp. Neurol. 67, 16–29. doi: 10.1097/nen.0b013e31815f3899
Perry, D. C., Lehmann, M., Yokoyama, J. S., Karydas, A., Lee, J. J., Coppola, G., et al. (2013). Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol. 70, 774–778. doi: 10.1001/2013.jamaneurol.393
Rogaeva, E., and Hardy, J. (2008). Gaucher and Parkinson diseases: unexpectedly related. Neurology 70, 2272–2273. doi: 10.1212/01.wnl.0000314657.92762.0f
Sargeant, T. J., Wang, S., Bradley, J., Smith, N. J., Raha, A. A., McNair, R., et al. (2011). Adeno-associated virus-mediated expression of β-hexosaminidase prevents neuronal loss in the Sandhoff mouse brain. Hum. Mol. Genet. 20, 4371–4380. doi: 10.1093/hmg/ddr364
Smith, K. R., Damiano, J., Franceschetti, S., Carpenter, S., Canafoglia, L., Morbin, M., et al. (2012). Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am. J. Hum. Genet. 90, 1102–1107. doi: 10.1016/j.ajhg.2012.04.021
Tanaka, Y., Chambers, J. K., Matsuwaki, T., Yamanouchi, K., and Nishihara, M. (2014). Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. Acta Neuropathol. Commun. 2:78. doi: 10.1186/s40478-014-0078-x
Keywords: Alzheimer's disease (AD), Parkinson's disease, frontotemporal dementia (FTD), lysosomal storage diseases, lysosomes, neurodegenerative diseases, progranulin, glucocerebrosidase gene
Citation: Sargeant TJ (2016) Commentary: Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. Front. Aging Neurosci. 8:11. doi: 10.3389/fnagi.2016.00011
Received: 20 September 2015; Accepted: 14 January 2016;
Published: 03 February 2016.
Edited by:
Fernanda Laezza, University of Texas Medical Branch, USAReviewed by:
Luc Buee, Institut National de la Santé et de la Recherche Médicale, FranceCopyright © 2016 Sargeant. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Timothy J. Sargeant, tim.sargeant@sahmri.com